

Special Issue

Newborn Screening for Pompe Disease

Message from the Guest Editors

Newborn screening is important for the early diagnosis and treatment of Pompe disease. The initial successes of Pompe disease newborn screening were from Taiwan, and currently, a good number of newborn screening programs have already started or are in the planning stages. However, screening for Pompe disease is not without its difficulties. There are a few assays available for screening. The accuracy of the assay as well as the screening algorithm determine the false positive and negative rates. Confirming diagnosis can be difficult, and genotype–phenotype correlation may not be established. Decision about when to initiate treatment, especially for late-onset Pompe disease, is difficult. To add to this, all these problems are further diverse among different ethnic groups. Through this Special Issue, experts in the field of newborn screening can share experiences in Pompe disease and help to accumulate data concerning prevalence, genotype, and phenotypes. More general readers of the Journal can also have the chance to understand Pompe disease and its screening. We think this Special Issue is just in time, and we thank all contributing authors in advance.

Guest Editors

Prof. Dr. Wuh-Liang Hwu

Prof. Dr. Yin-Hsiu Chien

Dr. Raymond Wang

Deadline for manuscript submissions

closed (31 December 2019)



International Journal of Neonatal Screening

an Open Access Journal
Published by MDPI

Impact Factor 4.0
CiteScore 6.7
Indexed in PubMed



mdpi.com/si/29689

*International Journal of
Neonatal Screening*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ijns@mdpi.com

mdpi.com/journal/

IJNS





International Journal of Neonatal Screening

an Open Access Journal
Published by MDPI

Impact Factor 4.0
CiteScore 6.7
Indexed in PubMed



[mdpi.com/journal/
IJNS](https://mdpi.com/journal/IJNS)



About the Journal

Message from the Editorial Board

Editors-in-Chief

Dr. Peter C. J. I. Schielen

Office of the International Society for Neonatal Screening, Reigerskamp
273, 3607 HP Maarssen, The Netherlands

Dr. Ralph Fingerhut

Newborn Screening and Metabolic Laboratory, Synlab MVZ Weiden, D-
92637 Weiden, Germany

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed,
PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Genetics and Heredity) / CiteScore - Q1
(Pediatrics, Perinatology and Child Health)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 28.8 days after
submission; acceptance to publication is undertaken in 6.5
days (median values for papers published in this journal in
the first half of 2024).